MONOCLONAL ANTIBODIES AND ANTIBODY-DRUG CONJUGATES IN PRECISION CANCER THERAPY
Keywords:
monoclonal antibodies; antibody-drug conjugates; precision oncology; targeted therapy; linker; payload; biomarker; resistance; therapeutic indexAbstract
Precision oncology increasingly relies on therapeutic platforms that couple molecular recognition with mechanism-specific killing. Monoclonal antibodies (mAbs) provide high-affinity recognition of tumor-associated antigens and can inhibit signaling, recruit immune effector functions or block immune checkpoints, whereas antibody-drug conjugates (ADCs) extend this concept by attaching a potent cytotoxic payload to a tumor-targeting antibody through a chemically engineered linker. This structured review evaluates how antibody biology, antigen selection, linker chemistry, payload class, drug-to-antibody ratio, internalization, bystander activity and biomarker stratification determine the therapeutic index of modern antibody-based cancer therapy. Literature was selected from peer-reviewed international sources emphasizing recent reviews and landmark phase III trials. The evidence indicates that precision selection of target and molecular format is as important as payload potency. New-generation ADCs can produce activity in tumors with heterogeneous or relatively low antigen expression, but their benefits are constrained by interstitial lung disease, myelosuppression, neuropathy, ocular toxicity, antigen loss, altered intracellular trafficking and multidrug resistance. Clinical examples including trastuzumab deruxtecan, trastuzumab emtansine, sacituzumab govitecan and enfortumab vedotin demonstrate that antibody-guided cytotoxic delivery can extend the clinically actionable range of tumor biomarkers. Future progress is likely to depend on site-specific conjugation, improved linker stability, novel payloads, bispecific and dual-payload ADCs, biomarker-adaptive dosing, and integration of spatial and longitudinal tumor profiling. These developments position antibody therapeutics as a central component of precision cancer medicine while emphasizing the need for individualized risk-benefit assessment.
References
1.Paul, S., Konig, M. F., Pardoll, D. M., Bettegowda, C., Papadopoulos, N., Wright, K. M., Gabelli, S. B., Ho, M., van Elsas, A., et al. (2024). Cancer therapy with antibodies. Nature Reviews Cancer, 24, 399-426. https://doi.org/10.1038/s41568-024-00690-x
2.Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021). Unlocking the potential of antibody-drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 18, 327-344. https://doi.org/10.1038/s41571-021-00470-8
3.Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody-drug conjugates. Nature Reviews Clinical Oncology, 21, 203-223. https://doi.org/10.1038/s41571-023-00850-2
4.Tarantino, P., Ricciuti, B., Pradhan, S. M., et al. (2023). Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nature Reviews Clinical Oncology, 20, 558-576. https://doi.org/10.1038/s41571-023-00783-w
5.Tsuchikama, K., & An, Z. (2018). Antibody-drug conjugates: Recent advances in conjugation and linker chemistries. Protein & Cell, 9(1), 33-46. https://doi.org/10.1007/s13238-016-0323-0
6.Jabbour, E., Paul, S., & Kantarjian, H. (2021). The clinical development of antibody-drug conjugates - lessons from leukaemia. Nature Reviews Clinical Oncology, 18, 418-433. https://doi.org/10.1038/s41571-021-00484-2
7.Modi, S., Jacot, W., Yamashita, T., et al. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387, 9-20. https://doi.org/10.1056/NEJMoa2203690
8.Cortes, J., Kim, S.-B., Chung, W.-P., et al. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New England Journal of Medicine, 386, 1143-1154. https://doi.org/10.1056/NEJMoa2115022
9.Bardia, A., Hurvitz, S. A., Tolaney, S. M., et al. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine, 384, 1529-1541. https://doi.org/10.1056/NEJMoa2028485
10.Powles, T., Rosenberg, J. E., Sonpavde, G. P., et al. (2021). Enfortumab vedotin in previously treated advanced urothelial carcinoma. New England Journal of Medicine, 384, 1125-1135. https://doi.org/10.1056/NEJMoa2035807
11.Goebeler, M.-E., Stuhler, G., & Bargou, R. (2024). Bispecific and multispecific antibodies in oncology: Opportunities and challenges. Nature Reviews Clinical Oncology, 21, 539-560. https://doi.org/10.1038/s41571-024-00905-y
12.Coats, S., Williams, M., Kebble, B., Dixit, R., Tseng, L., Yao, N.-S., Tice, D. A., & Soria, J.-C. (2019). Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index. Clinical Cancer Research, 25(18), 5441-5448. https://doi.org/10.1158/1078-0432.CCR-19-0272
13.Loganzo, F., Sung, M., & Gerber, H.-P. (2016). Mechanisms of resistance to antibody-drug conjugates. Molecular Cancer Therapeutics, 15(12), 2825-2834. https://doi.org/10.1158/1535-7163.MCT-16-0408
